Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). Shareholders who purchased shares of SKYE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/skye-bioscience-inc-loss-submission-form/? ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of CarMax, Inc. (NYSE: KMX). Shareholders who purchased shares of KMX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. 21% CONTACT US HERE: https://securitiesclasslaw.com/securities/carmax-inc-loss-submission-form/?id=178576&from=4 ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of James Hardie Industries plc. (NYSE: JHX). Shareholders who purchased shares of JHX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Emai ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Molina Healthcare, Inc. (NYSE: MOH). Shareholders who purchased shares of MOH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/molina-healthcare-inc-loss-submission-form/ ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Firefly Aerospace Inc. (NASDAQ: FLY). Shareholders who purchased shares of FLY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/firefly-aerospace-inc-loss-submission-for ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to significant stock price decline [2][5][6][8]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to contact them for discussing legal options [1]. - There is a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against MoonLake [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [5]. - Specific allegations include misleading claims about SLK's clinical benefits and its supposed superiority over BIMZELX, which were not supported by evidence [5]. - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 [6][8].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Financial Performance - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% decline year-over-year. The net income was $242.5 million, marking a 43% year-over-year decline [6]. Customer Dynamics - The lawsuit alleges that while Synopsys claimed its customers relied on its IP to minimize integration risk and speed time to market, the reality was that customers began requiring more customization for IP components, negatively impacting the economics of the Design IP business and threatening its business model [5]. Stock Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys' stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, a decline of nearly 36% [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. related to misleading statements about the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [3][6]. Group 1: Legal Action and Investor Rights - Investors who purchased aTyr securities between January 16, 2025, and September 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [2][3]. - A federal securities class action has been filed against aTyr, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [3][8]. Group 2: Allegations Against aTyr Pharma - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements regarding Efzofitimod's efficacy, particularly its ability to allow patients to taper off steroids completely [6]. - In the EFZO-FIT study, efzofitimod showed no significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - The study reported that complete steroid withdrawal was achieved in 52.6% of patients treated with efzofitimod versus 40.2% on placebo [7]. Group 3: Market Impact - Following the release of the study results, aTyr's stock price plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].

Core Viewpoint - Class action lawsuits have been filed against multiple publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and prospects, leading to investor losses. Group 1: Stride, Inc. (NYSE: LRN) - The class period for Stride, Inc. is from October 22, 2024, to October 28, 2025, with a lead plaintiff deadline of January 12, 2026 [2] - Allegations include inflating enrollment numbers by retaining "ghost students," cutting staffing costs by overloading teachers, ignoring compliance requirements, suppressing whistleblowers, and losing student enrollments [2] Group 2: Primo Brands Corporation (NYSE: PRMB) - The class period for Primo Brands Corporation is from June 17, 2024, to November 6, 2025, with a lead plaintiff deadline of January 12, 2026 [3] - Allegations include poor merger integration with BlueTriton Brands, major supply disruptions affecting customers, and misleading positive statements about the company's business [3] Group 3: Freeport-McMoran Inc. (NYSE: FCX) - The class period for Freeport-McMoran Inc. is from February 15, 2022, to September 24, 2025, with a lead plaintiff deadline of January 12, 2026 [4] - Allegations include inadequate safety measures at the Grasberg Block Cave mine, which posed risks to workers and led to regulatory and reputational risks, along with misleading positive statements about the company's operations [4] Group 4: Perrigo Company plc (NYSE: PRGO) - The class period for Perrigo Company plc is from February 27, 2023, to November 4, 2025, with a lead plaintiff deadline of January 16, 2026 [6] - Allegations include significant underinvestment in the infant formula business acquired from Nestlé, the need for substantial capital expenditures for remediation, and overstated financial results due to manufacturing deficiencies [6]

Accessibility StatementSkip Navigation NEW YORK, Nov. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in CarMax, Inc. ("CarMax, Inc." or the "Company") (NYSE: KMX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of CarMax, Inc. investors who were adversely affected by alleged securities fraud between June 20, 2025 and September 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk. ...